BMRA Logo

Biomerica, Inc. (BMRA) 

NASDAQ
Market Cap
$4.65M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
573 of 960
Rank in Industry
69 of 120

Largest Insider Buys in Sector

BMRA Stock Price History Chart

BMRA Stock Performance

About Biomerica, Inc.

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely …

Insider Activity of Biomerica, Inc.

Over the last 12 months, insiders at Biomerica, Inc. have bought $0 and sold $0 worth of Biomerica, Inc. stock.

On average, over the past 5 years, insiders at Biomerica, Inc. have bought $45,752 and sold $80,878 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 200 shares for transaction amount of $310 was made by Irani Zackary S. (Chief Executive Officer) on 2023‑05‑25.

List of Insider Buy and Sell Transactions, Biomerica, Inc.

2023-05-25PurchaseChief Executive Officer
200
0.0015%
$1.55$310-33.33%
2023-05-24PurchaseChief Executive Officer
500
0.0037%
$1.61$805-37.04%
2023-05-12PurchaseChief Executive Officer
1,700
0.0132%
$1.17$1,989-7.14%
2023-05-10PurchaseChief Executive Officer
500
0.0038%
$1.27$635-16.40%
2023-05-09PurchaseChief Executive Officer
300
0.0024%
$1.39$417-18.60%
2023-05-04PurchaseChief Executive Officer
1,000
0.0073%
$1.36$1,360-23.19%
2023-04-28PurchaseChief Executive Officer
1,800
0.0135%
$1.34$2,412-18.80%
2023-04-27PurchaseChief Executive Officer
2,600
0.0194%
$1.31$3,406-16.92%
2023-04-26PurchaseChief Executive Officer
7,000
0.0528%
$1.26$8,820-12.90%
2023-01-27PurchaseExecutive Vice Chairman
1,538
0.0116%
$2.94$4,522-55.86%
2023-01-26Purchasedirector
2,190
0.016%
$2.96$6,482-57.33%
2023-01-25PurchaseChief Executive Officer
1,800
0.013%
$2.85$5,130-55.82%
2023-01-24PurchaseChief Executive Officer
2,000
0.0149%
$2.81$5,620-53.93%
2020-10-26Purchasedirector
9,100
0.0773%
$5.45$49,595-8.79%
2020-04-21Saledirector
5,000
0.0429%
$8.11$40,532-16.09%
2020-04-17Saledirector
5,000
0.0419%
$8.07$40,346-17.46%
2018-02-09PurchaseChief Executive Officer
500
0.0057%
$3.83$1,915-7.18%
2018-02-02PurchaseChief Executive Officer
1,000
0.0119%
$3.96$3,960-6.68%
2018-01-25PurchaseChief Executive Officer
2,039
0.0237%
$4.03$8,209-9.16%
2018-01-25Purchasedirector
8,200
0.0992%
$4.18$34,276-9.16%

Insider Historical Profitability

<0.0001%
Irani Zackary S.Chief Executive Officer
1020560
6.067%
$0.28340<0.0001%
MOORE JANET TRUST DTD 8/21/98
635977
3.7807%
$0.2810<0.0001%
IRANI ZACKARYChief Executive Officer
271526
1.6142%
$0.2810
MOORE JANETChief Financial Officer
140720
0.8365%
$0.2826<0.0001%
CANO FRANCISdirector
133736
0.795%
$0.2870<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Granahan Investment Management$939,762.006.721.13M+4.33%+$38,979.190.03
Wasatch Advisors$793,116.005.67953,2640%+$0<0.01
The Vanguard Group$506,992.003.62609,3650%+$0<0.0001
Russell Investments Group Ltd$187,561.001.34225,435+11.84%+$19,861.41<0.0001
BlackRock$124,035.000.89149,081-0.42%-$520.83<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.